ArticleBMC ophthalmology2026
Comparative outcomes of posterior sub-Tenon triamcinolone for pseudophakic cystoid macular edema in diabetic and non-diabetic patients: a retrospective study.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare the anatomical and functional outcomes of posterior sub-Tenon triamcinolone (PST) in the treatment of pseudophakic cystoid macular edema (PCME) between diabetic and non-diabetic patients.
methodsThis retrospective study reviewed the medical records of patients who received PST for PCME following uncomplicated phacoemulsification with intraocular lens implantation between 2018 and 2021, with a minimum follow-up period of six months. A total of 43 eyes were included: 24 from non-diabetic patients (Group 1) and 19 from diabetic patients without diabetic retinopathy (Group 2). The mean HbA1c level in the diabetic group was 7.4 ± 1.1%, indicating moderately controlled diabetes. Best-corrected visual acuity (BCVA, LogMAR), central macular thickness (CMT), and intraocular pressure (IOP) were assessed at baseline and at 1, 3, and 6 months after PST treatment.
resultsBoth groups demonstrated statistically significant improvements in BCVA and reductions in CMT at all follow-up visits (p < 0.05). In Group 1, mean CMT decreased from 412 ± 144 μm to 296 ± 65 μm, and BCVA improved from 0.64 ± 0.22 to 0.14 ± 0.08. Similarly, in Group 2, mean CMT decreased from 426 ± 154 μm to 301 ± 70 μm, and BCVA improved from 0.69 ± 0.26 to 0.15 ± 0.07. No significant intergroup differences were observed in changes in BCVA or CMT (p > 0.05). Intraocular pressure remained stable throughout the follow-up period in both groups.
conclusionsThe findings indicate that the presence of diabetes mellitus without retinopathy does not significantly influence the anatomical or functional response to PST therapy in patients with PCME. PST appears to be an effective and well-tolerated second-line treatment for PCME in both diabetic and non-diabetic patients following uncomplicated cataract surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.